close

Agreements

Date: 2011-09-27

Type of information: R&D agreement

Compound: DACC formulated siRNAs

Company: Silence Therapeutics (UK) undisclosed top 10 pharma company

Therapeutic area:

Type agreement:

R&D

Action mechanism:

DACC is a novel lipid delivery system that includes Silence’s proprietary lipid AtuFect and is used to embed siRNAs into a multiple lipid bi-layer structure. In preclinical models, the DACC delivery system has demonstrated highly focused delivery to lung tissue and sustained knockdown of the desired target gene expression in this particular cell type.

Disease: undisclosed

Details:

Silence Therapeutics has entered into an agreement with one of the world’s leading global pharmaceutical companies to investigate the application of Silence’s proprietary DACC delivery technology for intravenous delivery of short interfering RNA sequences (“siRNAs”) to the pulmonary vascular endothelium. Under the terms of the agreement, Silence’s partner will provide Silence with specific siRNAs, which Silence will formulate with its DACC delivery system. Silence and its partner will undertake in vitro and in vivo studies of the DACC formulated siRNAs developed under the agreement and select lead candidates for further evaluation.

Financial terms:

Financial terms were not disclosed.

Latest news:

Is general: Yes